FORTUNE -- The Nasdaq boosters can't be kept down: The recent selloff, they insist, is a frenzied overreaction that's serving up even better buys. On April 10, the Nasdaq composite index fell 130 points, or 3.1%, marking its largest one-day loss since Nov. 9, 2011, when it fell 3.9%.
The sharp re-pricing is well-deserved. Over time the Nasdaq will careen through spikes and valleys as usual, but the overall trajectory should be downward. In fact, the big losers in the sudden rout are precisely the stocks that grew into the most extravagantly expensive corner of the index. That group, more than any other, made the Nasdaq soar. Now it's a millstone.
The wildly overpriced stocks fall into two main areas, social networking and biotech. Let's examine the fantastic run experienced by eight companies in those categories. They're mostly the ones with the highest market caps: In social networking, the group comprises Facebook (FB), Google (GOOG), and Baidu (BID) of China; the biotech players are Alexion (ALXN), Gilead (GILD), Celgene (CELG), Biogen (BIIB), and Amgen (AMGN).
At the start of 2013, the total value of those eight stocks stood at around $570 billion, accounting for 18% of the Nasdaq 100's aggregate market cap of $3.1 trillion. (The Nasdaq 100 consists of the 100 largest companies in the overall index, ranked by market cap.)
Since then, the Nasdaq has gone on a tear, rising by 39% by April 8, the day before the selloff. But the combined value of the eight high-flyers jumped by more than 80%, more than double the overall gain in the index. Alexion rose 66%, Celgene 88%, Gilead 92%, Biogen 104%, and Facebook 122%. Only Amgen -- it gained a relatively modest 40% -- failed to beat the market by a wide margin.
By April 8, the value of those eight stocks had swelled from 18% of the Nasdaq 100's total market cap to almost one-quarter, an increase of over 6 percentage points.
And they became really, really expensive. The price-to-earnings ratios grew to 97 at Facebook and 113 at Alexion. The only company with a multiple below 28 (the number for Google) was Amgen at 17.
Over their past four quarters, the eight companies have posted combined earnings of $28 billion, vs. a combined market value of more than $1 trillion. Hence, the group, taken as a whole, is selling at 37 times profits.
If investors seek an 8% annual return from holding these volatile stocks, these companies will need a growth spurt in earnings of 15% annually for eight years, so that their profits would triple over that period. It's unlikely to happen.
The Nasdaq problem underscores a glaring weakness in cap-weighted indexes. As the prices of our eight sprinters outraced the rest of the index, a bigger and bigger share of an investor's holdings shifted to the most expensive stocks. If you kept adding money to a Nasdaq fund over that period, you were simply buying increasing portions of the overpriced stuff with every purchase.
That's the opposite of a Warren Buffett-style value strategy. Nasdaq investors are now stuck with far too much money in pricey shares that are cruisin' for a bruisin'. This crazy market is finally making a turn that makes perfect sense.
Even after the recent drop in the Nasdaq, investors are too pumped about technology stocks.
FORTUNE -- For tech stocks, growth may no longer be coming at a reasonable price, even after the recent pull-back.
Technology stocks are down 6% since they peaked in early March. And that drop is larger than the dip in the general market during the same time period.
But that doesn't mean there are bargains to be had. The average MOREStephen Gandel, senior editor - Apr 8, 2014 5:00 AM ET
Why the market jolt last week was the start of a sobering reality check for tech stocks.
FORTUNE -- Market prognosticators have conjured up many a reason for the two-day rout of stocks on Thursday and Friday, which sent the Dow Jones Industrial Average (INDU) plunging 494 points (3%) and the S&P 500 (SPX) down 55 points (3%). Some blamed the slowdown in China's perpetual manufacturing machine; others, the fears of MOREShawn Tully, senior editor-at-large - Jan 27, 2014 5:00 AM ET
The recent swings in Apple stock prove that a few simple rules of investing always hold true.
FORTUNE -- For most people, Apple mania means buying the company's products and playing with them. But for us financial voyeur types, the fun comes from watching the lunatic lurching of Apple's stock price.
You gotta love it. From the start of last year through its all-time closing high on Sept. 19, Wilshire Associate says, MOREAllan Sloan, senior editor-at-large - Feb 6, 2013 5:00 AM ET
What was once a growth story is now a growth stock and a value play.
By Jon Birger, contributor
FORTUNE -- I'm a nervous investor, so the notion of having all my money in any one stock is anathema. That said, I've owned some Apple (AAPL) for years. My "aha!" moment came when I replaced my old PC with a MacBook in 2009, and I've bought more shares since.
Three years ago, MOREDec 6, 2012 5:00 AM ET
Loading up on the tech giant's shares has been a winning strategy.
By Jon Birger, contributor
FORTUNE -- Just thinking about Terry and Jeanne Gregory's portfolio can be a little scary. Retirees now living in Honolulu, the Gregorys have basically their entire life savings -- about $2.5 million -- invested in just one stock: Apple Inc.
The Gregorys' love affair with Apple (AAPL) flouts every bit of investment advice doled out by MOREDec 6, 2012 5:00 AM ET
Despite a sizable plunge from spring highs, it's not yet game over for Zynga.
By Ryan Derousseau, contributor
FORTUNE -- Unlike its social media cousin Facebook, social-gaming company Zynga had a successful IPO. Priced at $10 a share in December 2011, Zynga (ZNGA) went public with a market cap of $7 billion. But after a couple of disastrous quarters -- highlighted by a decline in paying players of core games like MORENov 21, 2012 5:00 AM ET
Henry Ellenbogen scouts for small-cap companies and even the occasional not-yet-public startup.
By Mina Kimes, writer
FORTUNE -- Baltimore, the home of old-school mutual fund giant T. Rowe Price, is a long way from the startup scene in Silicon Valley. Henry Ellenbogen, who runs the $9.6 billion T. Rowe Price New Horizons Fund (PRNHX), straddles both worlds. He's constantly prowling for promising tech startups, spending about 100 days a year on MORESep 25, 2012 5:00 AM ET
No one ever said insider traders were geniuses, and the guys fingered Wednesday in a $32 million tech stock scam won't change that.
The feds arrested corporate lawyer Matthew Kluger and Garrett Bauer, a registered broker who worked briefly for two no-name Wall Street firms, and charged them and a third, unnamed, co-conspirator with illegally trading ahead of 11 mergers over six years.
Kluger "repeatedly stole material nonpublic information about pending mergers MOREColin Barr - Apr 6, 2011 12:56 PM ET
|GM's recalled Cobalt was a failure from the start|
|Michaels hack hit 3 million|
|Ousted Yahoo exec gets $58 million golden parachute|
|Detroit pension cuts hit civilian workers hardest|
|Canadians arrest a Heartbleed hacker|